Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

unknown267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

NCT04094909
unknownphase_3

Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

NCT02001168
terminatedphase_1

rhEndostatin Protein Involving Pediatric Patients With Cancer

NCT00165373

Clinical Trials (3)

Showing 3 of 3 trials
NCT04094909Phase 2

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Unknown
NCT02001168Phase 3

Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Unknown
NCT00165373Phase 1

rhEndostatin Protein Involving Pediatric Patients With Cancer

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3